跳至主要内容

Medicilon Ophthalmic Animal Models

 Medicilon Ophthalmic Animal Models

Dry eye, also known as dry eye disease (DED), dry eye syndrome, and keratoconjunctivitis sicca (KCS), is a multifactorial disease of the ocular surface. Dry eye is characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiologic roles.
Dry eyes affect a significant number of people, the cause of dry eye is multifactorial, in which ocular, anatomical and systemic factors play crucial roles. Prompt treatment significantly improves long-term quality of life, provides relief from dry eyes, and improves outcomes.

Model of Dry Eye Syndrome

Healthy rats were selected and given subcutaneous injections of scopolamine four times daily for 4 weeks and placed in dry room. Schemer‘s test and corneal conjunctiva stained with tiger red and fluorescein were performed before administration and on the 1st, 3rd, 5th, 7th, 14th, and 28th days after administration. The animals were euthanized on the 35th day after administration, and the conjunctiva, cornea, and lacrimal gland tissues were taken for light microscopic examination.

Testing parameters

  • Tear film break up time (BUT)
  • Schemer’s test
  • Slit Lamp exam: Corneal fluorescent staining test
  • Histopathology
Medicilon Ophthalmic Animal Models
Medicilon Ophthalmic Animal Models
Medicilon has established ocular diseases models, including the Conjunctival tissue proliferation and NV, Diabetic retinopathy (DR), Choroidal neovascularization (CNV) and subretinal fibrosis, Corneal neovascularization (Corneal NV), Retinal neovascularization, Acute ocular inflammation, and dry eye models. Learn More.

Schimer test results (tear secretion, mm)

Schimer test results (tear secretion, mm)​

Methods

After suctioning off the excess tear fluid from eyes, take 5 × 35 mm test paper with scale, fold one end back for 5 mm, gently put it into the middle and outer 1/3 of the inferior conjunctival sac of the testing eyes, take out the filter paper after 5 minutes and measure the wet length. Generally, 10-30 mm/ 5 min is normal. Less than 5 mm can be diagnosed as tear deficiency, 6-10 mm may be suspected of decreased secretion, and more than 10 mm is normal. If the filter paper is fully wet in less than 5 minutes, the time of full wetness will be recorded.

Tear film break-up time(s)

Tear film break-up time(s)​

Methods

Drop 1 µL of 10 g/L fluorescein sodium into the conjunctival sac and close the eyelid, observe under slit lamp microscope with the cobalt blue light. After three blink reflexes (BR), the time from the last BR to the appearance of the first dark spot in the cornea is defined as tear film break-up time.

Fluorescein staining

Fluorescein staining​

Methods

Positive results of fluorescence staining reflect corneal epithelial cell defects, the cornea is divided into four quadrants, 0 points for no staining, three grades for light, medium, and heavy staining, 1 point for less than five staining dots, 3 points for lumps or filaments staining, and 2 points between the above two, total 0-12 points.

Slit lamp examination (typical symptom I)

Slit lamp examination (typical symptom I)

Slit lamp examination (typical symptom ll)

Slit lamp examination (typical symptom II)

Slit lamp examination (typical symptom lll)

Slit lamp examination (typical symptom III)

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...